Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of moderate hepatic impairment on the pharmacokinetics and safety of keverprazan hydrochloride tablets
CTR20244070Phase 4Completed
- Sponsor
- 江苏柯菲平医药股份有限公司/ 南京柯菲平盛辉制药有限公司
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of keverprazan in erosive esophagitis (EE), duodenal ulcer, sponsored by 江苏柯菲平医药股份有限公司/ 南京柯菲平盛辉制药有限公司. Started Dec 2024; status: completed.
02
Drugs
keverprazan
03
Conditions
erosive esophagitis (EE)duodenal ulcer
Beyond the preview
Go deeper on CTR20244070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244070.